Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Indian REITs yield higher than US, Singapore, remain compelling bet’ : Anurag Mathur
24/09/2025
Gold steady near record high as markets assess Powell's comment
24/09/2025
Asian stocks edge lower after mixed Fed signals
24/09/2025
India may raise foreign investment limit in PSU banks
24/09/2025
Digital euro likely to be rolled out in mid-2029 : ECB's Piero Cipollone
24/09/2025
Complacency and not valuations, real risk : BlackRock Quant Head
24/09/2025
